Ward, R. A. et al. Challenges and alternatives in most cancers drug resistance. Chem. Rev. 121, 3297–3351 (2021).
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunogenic cell demise in most cancers and infectious illness. Nat. Rev. Immunol. 17, 97–111 (2017).
Thibaudin, M. et al. First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal most cancers: a section 1b/2 trial. Nat. Med. 29, 2087–2098 (2023).
Zhou, C. et al. Outcomes and toxicities of immune checkpoint inhibitors in colorectal most cancers: a real-world retrospective evaluation. Most cancers Commun. 41, 921–924 (2021).
Schmitt, M. et al. Colon tumour cell demise causes mTOR dependence by paracrine P2X4 stimulation. Nature 612, 347–353 (2022).
Mariya, T. et al. Prognostic affect of human leukocyte antigen class I expression and affiliation of platinum resistance with immunologic profiles in epithelial ovarian most cancers. Most cancers Immunol. Res. 2, 1220–1229 (2014).
Giddings, E. L. et al. Mitochondrial ATP fuels ABC transporter-mediated drug efflux in most cancers chemoresistance. Nat. Commun. 12, 2804 (2021).
Wu, Z. et al. Mitochondrial DNA stress signalling protects the nuclear genome. Nat. Metab. 1, 1209–1218 (2019).
Lao, L. et al. CD8+ T cell-dependent transforming of the tumor microenvironment overcomes chemoresistance. Most cancers Immunol. Res. 11, 320–338 (2023).
Kang, B. H. et al. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone community. Cell 131, 257–270 (2007).
Wang, X. et al. Cyclophilin D deficiency attenuates mitochondrial perturbation and ameliorates hepatic steatosis. Hepatology 68, 62–77 (2018).
Zhao, Q. et al. Concentrating on mitochondria-located circRNA SCAR alleviates NASH through decreasing mROS output. Cell 183, 76–93.e22 (2020).
Denorme, F. et al. Platelet necrosis mediates ischemic stroke end result in mice. Blood 135, 429–440 (2020).
Feng, Y., Madungwe, N. B., Tombo, N., Li, L. & Bopassa, J. C. Summary 420: RIP3 interacts with mitofilin within the inside membrane of mitochondria to induce cardiomyocytes necrosis after ischemia/reperfusion. Circ. Res. 123, A420 (2018).
Costantino, E. et al. TRAP1, a novel mitochondrial chaperone liable for multi-drug resistance and safety from apoptotis in human colorectal carcinoma cells. Most cancers Lett. 279, 39–46 (2009).
Yoon, N. G. et al. Mitoquinone inactivates mitochondrial chaperone TRAP1 by blocking the shopper binding web site. J. Am. Chem. Soc. 143, 19684–19696 (2021).
Gewirth, D. T. Paralog particular Hsp90 inhibitors—a quick historical past and a brilliant future. Curr. Prime. Med. Chem. 16, 2779–2791 (2016).
Tong, S., Moyo, B., Lee, C. M., Leong, Okay. & Bao, G. Engineered supplies for in vivo supply of genome-editing equipment. Nat. Rev. Mater. 4, 726–737 (2019).
Abramson, A. et al. Oral mRNA supply utilizing capsule-mediated gastrointestinal tissue injections. Matter 5, 975–987 (2022).
Yoo, J., Nhean, S., Vogel, P., Rybkin, I. I. & Kostoff, D. Implementation of oral chemotherapy administration program within the massive built-in well being care system and its affect on affected person security. J. Clin. Oncol. 36, 279 (2018).
Brown, T. D., Whitehead, Okay. A. & Mitragotri, S. Supplies for oral supply of proteins and peptides. Nat. Rev. Mater. 5, 127–148 (2020).
Li, B. et al. Trimethylamine N-oxide-derived zwitterionic polymers: a brand new class of ultralow fouling bioinspired supplies. Sci. Adv. 5, eaaw9562 (2019).
Shao, Q. & Jiang, S. Molecular understanding and design of zwitterionic supplies. Adv. Mater. 27, 15–26 (2015).
Bansil, R. & Turner, B. S. The biology of mucus: composition, synthesis and group. Adv. Drug Deliv. Rev. 124, 3–15 (2018).
Duncan, G. A., Jung, J., Hanes, J. & Suk, J. S. The mucus barrier to inhaled gene remedy. Mol. Ther. 24, 2043–2053 (2016).
Mirji, G. et al. The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic most cancers. Sci. Immunol. 7, eabn0704 (2022).
Teft, W. A. et al. Identification and characterization of trimethylamine-N-oxide uptake and efflux transporters. Mol. Pharm. 14, 310–318 (2017).
Kato, Y. et al. Artificial zwitterions as environment friendly non-permeable cryoprotectants. Comm. Chem. 4, 151 (2021).
Ganguly, P., Boserman, P., van der Vegt, N. F. A. & Shea, J.-E. Trimethylamine N-oxide counteracts urea denaturation by inhibiting protein–urea preferential interplay. J. Am. Chem. Soc. 140, 483–492 (2018).
Xie, W. J. et al. Giant hydrogen-bond mismatch between TMAO and urea promotes their hydrophobic affiliation. Chem 4, 2615–2627 (2018).
Landriscina, M. et al. TRAP1, a novel antiapoptotic gene liable for multidrug resistance in human colorectal carcinoma cells. J. Clin. Oncol. 27, 2541 (2009).
Chae, Y. C. et al. Management of tumor bioenergetics and survival stress signaling by mitochondrial HSP90s. Most cancers Cell 22, 331–344 (2012).
Ariës, I. M. et al. PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. J. Exp. Med. 215, 3094–3114 (2018).
Lu, L. et al. Nanoparticle-based oral supply techniques for colon focusing on: rules and design methods. Sci. Bull. 61, 670–681 (2016).
Hone Lopez, S. et al. The intestine wall’s potential as a accomplice for precision oncology in immune checkpoint remedy. Most cancers Deal with. Rev. 107, 102406 (2022).
Lee, Y., Kamada, N. & Moon, J. J. Oral nanomedicine for modulating immunity, intestinal barrier capabilities, and intestine microbiome. Adv. Drug Deliv. Rev. 179, 114021 (2021).
Zhao, Z. et al. Organoids. Nat. Rev. Strategies Prim. 2, 94 (2022).
Drost, J. & Clevers, H. Organoids in most cancers analysis. Nat. Rev. Most cancers 18, 407–418 (2018).
Li, X., Bechara, R., Zhao, J., McGeachy, M. J. & Gaffen, S. L. IL-17 receptor–based mostly signaling and implications for illness. Nat. Immunol. 20, 1594–1602 (2019).
Total, C. M. & Kleifeld, O. Validating matrix metalloproteinases as drug targets and anti-targets for most cancers remedy. Nat. Rev. Most cancers 6, 227–239 (2006).
Zhao, H. et al. Wnt signaling in colorectal most cancers: pathogenic position and therapeutic goal. Mol. Most cancers 21, 144 (2022).
Pan, Okay. & Xie, Y. LncRNA FOXC2-AS1 enhances FOXC2 mRNA stability to advertise colorectal most cancers development through activation of Ca2+-FAK sign pathway. Cell Loss of life Dis. 11, 434 (2020).
Baghdadi, M. et al. Chemotherapy-induced IL34 enhances immunosuppression by tumor-associated macrophages and mediates survival of chemoresistant lung most cancers cells. Most cancers Res. 76, 6030–6042 (2016).